期刊
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
卷 82, 期 5, 页码 1229-1244出版社
WILEY-BLACKWELL
DOI: 10.1111/bcp.12928
关键词
ageing; Hutchinson-Gilford Progeria syndrome (HGPS); lamin A; mTOR inhibitors; rapamycin; progeria-related diseases
资金
- A.I.Pro.Sa.B.
- Fondazione Del Monte Grant
- Rizzoli Orthopedic Institute
The mammalian target of rapamycin (mTOR) pathway is an highly conserved signal transduction axis involved in many cellular processes, such as cell growth, survival, transcription, translation, apoptosis, metabolism, motility and autophagy. Recently, this signalling pathway has come to the attention of the scientific community owing to the unexpected finding that inhibition of mTOR by rapamycin, an antibiotic with immunosuppressant and chemotherapeutic properties, extends lifespan in diverse animal models. Moreover, rapamycin has been reported to rescue the cellular phenotype in a progeroid syndrome [Hutchinson-Gilford Progeria syndrome (HGPS)] that recapitulates most of the traits of physiological ageing. The promising perspectives raised by these results warrant a better understanding of mTOR signalling and the potential applications of mTOR inhibitors to counteract ageing-associated diseases and increase longevity. This review is focused on these issues.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据